Olympus Corporation announced today the launch of the NBI+TXI™ observation mode, a new imaging capability for the EVIS X1™ endoscopy system CV-1500 Video System Center. The mode combines Narrow Band Imaging (NBI™) and Texture and Color Enhancement Imaging (TXI™) into a single view, aiming to improve diagnostic accuracy for lesions, including those associated with cancers. Sales will begin in Japan in November 2025, with other regions to follow pending regulatory approvals.
Since its initial launch in April 2020, the EVIS X1 system has offered advanced imaging technologies such as TXI, NBI, and RDI (Red Dichromatic Imaging) modes. The new NBI+TXI mode enhances brightness correction and contrast in NBI mode, enabling clearer visualization of vascular and mucosal patterns, particularly in darker areas. This could contribute to improved detection and diagnostic accuracy for cancers, which remain a significant health burden in Japan. According to 2021 statistics from the Ministry of Health, Labour and Welfare, colorectal cancer has the highest incidence rate (154,585 cases), followed by lung cancer (124,531 cases) and stomach cancer (112,881 cases). These cancers are also leading causes of death, with lung cancer first (75,762 deaths), colorectal cancer second (53,131 deaths), and stomach cancer fourth (38,771 deaths).
NBI mode, first introduced globally in 2006, revolutionized endoscopic imaging by improving visibility of features previously difficult to detect. The CV-1500 incorporates the latest NBI mode with improved brightness. TXI mode, introduced with the CV-1500, enhances lesion visibility through image enhancement technology under conventional light. The combination of both technologies in NBI+TXI mode is expected to further optimize contrast information in NBI images, supporting more precise examinations and treatments.
TXI mode supports better visibility of potential and extant lesions by enhancing texture, brightness, and color to define subtle tissue differences. It has the potential to reinvent white light in endoscopy, contributing to higher detection rates and improved qualitative diagnosis. NBI mode creates strong contrast between vessels and surrounding mucosa using specific blue and green wavelengths, aiding earlier detection and detailed visualization.
“We know that early detection improves patient care and outcomes,” said Kurt Heine, Senior Vice President and General Manager for Gastroenterology at Olympus. “Olympus is committed to providing the advanced endoscopic imaging physicians need to clearly visualize the GI tract and provide timely diagnoses and treatment. We're excited to expand upon the innovations of our EVIS X1 endoscopy system with this combined imaging mode capability and continue elevating the standard of care.”
Physicians attending JDDW, scheduled for October 30–November 1, 2025 at the Kobe Convention Center, will have the opportunity to see the combined NBI+TXI imaging mode firsthand. More information about Olympus and its products can be found at https://www.olympus-global.com/.
